Are you a medical professional looking for more information about certolizumab? Look no further! This ultimate guide has everything you need to know about this medication, including its uses, potential side effects, and who should avoid it. Whether you're new to prescribing certolizumab or simply want to refresh your knowledge on the topic, this comprehensive guide will provide you with all the necessary information. So sit back, relax, and let's dive into the world of certolizumab!
Certolizumab is a medication that belongs to a class of drugs called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, which is a protein produced by the body's immune system and can cause inflammation.
This medication is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis.
Unlike other TNF inhibitors, certolizumab has been developed without any mouse or human-derived components. Instead, it consists solely of recombinant humanized antibodies fused with polyethylene glycol (PEG), which helps extend its half-life in the bloodstream.
As with any medication, certolizumab may cause side effects. Common side effects of certolizumab include redness, swelling, itching or pain at the injection site. These symptoms are usually mild and go away within a few days.
Other common side effects of certolizumab include headache and upper respiratory tract infections such as sinusitis or the common cold. These side effects may also be mild and typically resolve on their own.
Less common but potentially serious side effects of certolizumab include severe allergic reactions such as difficulty breathing, chest tightness or swelling of the face, lips or tongue.
Certolizumab is a medication that works by suppressing the activity of tumor necrosis factor-alpha (TNF-alpha), which is associated with various inflammatory and autoimmune diseases. However, not everyone can take certolizumab safely.
If you are allergic to certolizumab or any of its ingredients, you should not take this medication as it may cause an allergic reaction. Additionally, if you have a current or past history of tuberculosis (TB) or other infections such as hepatitis.
Pregnant women must avoid using certolizumab unless absolutely necessary because there is insufficient data on its safety in pregnancy. Similarly, breastfeeding mothers must also exercise caution when using this drug since it can pass into breast milk and potentially harm nursing infants.
Certolizumab is a highly effective medication for treating various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. It works by blocking the action of TNF-alpha in the body which reduces inflammation and helps to alleviate symptoms.
While certolizumab can be an excellent option for patients who have not responded well to other treatments, it does come with some potentially serious side effects that need to be considered carefully before starting treatment.
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation